# Knoll Capital Management

> Knoll Capital Management is a VC fund backing Health Care, Biotechnology and Therapeutics. See 4 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Nov 2017
- Lead investor: 0%
- Last updated: Sep 2026

Knoll Capital Management is a venture capital firm thats invests in firms focused in information technology sector.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 75% |
| Biotechnology | 3 | 75% |
| Therapeutics | 2 | 50% |
| Pharmaceutical | 2 | 50% |
| Medical | 1 | 25% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 25% |
| Funding Round | 1 | 25% |
| Post-IPO Equity | 1 | 25% |
| Venture - Series Unknown | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ElectroCore | electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraineand acute treatment of migraine and episodic cluster headache. | $34M | Series B | Nov 29, 2017 | http://www.electrocore.com/ |
| Exicure | Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $11.2M | Venture - Series Unknown | Nov 06, 2017 | http://www.exicuretx.com/index.php |
| Bristol-Myers Squibb | Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. | $80M | Post-IPO Equity | Feb 21, 2017 | http://www.bms.com |
| Biohaven Pharmaceutical | Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipelineproducts include BHV3000-301, BHV3000-302, BHV3000-303, and others. | $80M |  | Nov 01, 2016 | http://biohavenpharma.com/ |

4 of 4 investments shown.

## Co-investors
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 2 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 2 deals together
- [Connecticut Innovations](https://shizune.co/investors/profile/connecticut-innovations) — VC Fund, 2 deals together
- Litmore Capital — VC Fund, 2 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Knoll Capital Management invest in?

Knoll Capital Management invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Knoll Capital Management last invest?

The most recent investment recorded for Knoll Capital Management closed in Nov 2017. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co